Kelun-Biotech (06990) disclosed its monthly return for the period ended 31 January 2026. The company’s total authorized share capital stood at RMB 233,185,969, reflecting no change during the month. Authorized shares consist of 162,769,979 H shares, 65,773,800 domestic shares, and 4,642,190 unlisted foreign shares, all with par value of RMB 1 each.

The total issued H shares remained at 162,769,979, with no treasury shares and no changes throughout January. The public float requirement of 22.09% for these shares continues to be met. Meanwhile, domestic shares and unlisted foreign shares both stayed unchanged at 65,773,800 and 4,642,190 shares, respectively.

The filing confirms that no share options, warrants, convertible securities, or other arrangements affecting share capital were issued or altered in January 2026. The company’s Joint Company Secretary submitted the necessary confirmations as required by relevant listing rules and regulations.